Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and p38 MAPK and provides a mouse model of hemolytic uremic syndrome

American Journal of Pathology

Volumn 166, Issue 1, 2005, Pages 323-339

  Korcheva, Veselina ^a   Wong, John ^a   Corless, Christopher ^b   Iordanov, Mihail ^a   Magun, Bruce ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RICIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; INFLAMMATION; INTOXICATION; KIDNEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STIMULATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 11144247941     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62256-0     Document Type: Article

References (111)

1. Franz DR, Jaax JK: Ricin toxin. Textbook of Military Medicine, Part 1. Warfare, Weaponry, and the Casualty: Medical Aspects of Chemical and Biological Warfare. Edited by FR Sidell, ET Takfuji, DR Franz. Washington, Office of the Surgeon General, Department of the Army, 1997, pp 631-642
2. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES: A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 2002, 20:3422-3427
3. Crompton R, Gall D: Georgi Markov - death in a pellet. Med Leg J 1980, 48:51-62
4. Barbieri L, Battelli MG, Stirpe F: Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1993, 1154:237-282
5. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Chen SL, Magun BE: Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol 1997, 17:3373-3381
6. Iordanov MS, Magun BE: Loss of cellular K+ mimics ribotoxic stress. Inhibition of protein synthesis and activation of the stress kinases SEK1/MKK4, stress-activated protein kinase/c-Jun NH2-terminal kinase 1, and p38/HOG1 by palytoxin. J Biol Chem 1998, 273:3528-3534
7. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Magun BE: Ultraviolet radiation triggers the ribotoxic stress response in mammalian cells. J Biol Chem 1998, 273:15794-15803
8. Iordanov MS, Magun BE: Different mechanisms of c-Jun NH(2)-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors. J Biol Chem 1999, 274:25801-25806
9. Iordanov MS, Choi RJ, Ryabinina OP, Dinh TH, Bright RK, Magun BE: The UV (ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor. Mol Cell Biol 2002, 22:5380-5394
10. Waskiewicz AJ, Cooper JA: Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 1995, 7:798-805
11. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869
12. Bingen A, Creppy EE, Gut JP, Dirheimer G, Kirn A: The Kupffer cell is the first target in ricin-induced hepatitis. J Submicrosc Cytol 1987, 19:247-256
13. Taylor CM, Williams JM, Lote CJ, Howie AJ, Thewles A, Wood JA, Milford DV, Raafat F, Chant I, Rose PE: A laboratory model of toxin-induced hemolytic uremic syndrome. Kidney Int 1999, 55:1367-1374
14. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB: Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002, 186:493-500
15. Paton JC, Paton AW: Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998, 11:450-479
16. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001, 60:831-846
17. Proulx F, Seidman EG, Karpman D: Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 2001, 50:163-171
18. O'Brien AD, Holmes RK: Shiga and Shiga-like toxins. Microbiol Rev 1987, 51:206-220
19. Olsnes S, Kozlov JV: Ricin. Toxicon 2001, 39:1723-1728
20. Cohen A, Hannigan GE, Williams BR, Lingwood CA: Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 1987, 262:17088-17091
21. Sandvig K, Grimmer S, Lauvrak SU, Torgersen ML, Skretting G, van Deurs B, Iversen TG: Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol 2002, 117:131-141
22. Rowe PC, Orrbine E, Wells GA, McLaine PN: Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric. Kidney Disease Reference Centre. J Pediatr 1991, 119:218-224
23. Thorpe CM: Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 2004, 38:1298-1303
24. Litalien C, Proulx F, Mariscalco MM, Robitaille P, Turgeon JP, Orrbine E, Rowe PC, McLaine PN, Seidman E: Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr Nephrol 1999, 13:840-845
25. Yamamoto T, Isokawa S, Miyata H, Yoshioka K: Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection. Nippon Jinzo Gakkai Shi 1999, 41:60-64
26. Lopez EL, Contrini MM, Devoto S, de Rosa MF, Grana MG, Genero MH, Canepa C, Gomez HF, Cleary TG: Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. Pediatr Infect Dis J 1995, 14:594-598
27. Kreitman RJ: Immunotoxins in cancer therapy. Curr Opin Immunol 1999, 11:570-578
28. Frankel AE, Tagge EP, Willingham MC: Clinical trials of targeted toxins. Semin Cancer Biol 1995, 6:307-317
29. Engert A, Sausville EA, Vitetta E: The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr Top Microbiol Immunol 1998, 234:13-33
30. Hochberg Y, Benjamini Y: More powerful procedures for multiple significance testing. Stat Med 1990, 9:811-818
31. Chen CC, Wang JK: p38 but not P44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol 1999, 55:481-488
32. Chakravortty D, Kato Y, Sugiyama T, Koide N, Mu MM, Yoshida T, Yokochi T: Inhibition of caspase 3 abrogates lipopolysaccharide-induced nitric oxide production by preventing activation of NF-kappaB and c-Jun NH2-terminal kinase/stress-activated protein kinase in RAW 264.7 murine macrophage cells. Infect Immun 2001, 69:1315-1321
33. Yamasaki S, Nakashima T, Kawakami A, Miyashita T, Tanaka F, Ida H, Migita K, Origuchi T, Eguchi K: Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells. Rheumatology (Oxford) 2004, 43:448-452
34. Higuchi S, Tamura T, Oda T: Cross-talk between the pathways leading to the induction of apoptosis and the secretion of tumor necrosis factor-alpha in ricin-treated RAW 264.7 cells. J Biochem (Tokyo) 2003, 134:927-933
35. Hassoun E, Wang X: Ricin-induced toxicity in the macrophage J744A. 1 cells: the role of TNF-alpha and the modulation effects of TNF-alpha polyclonal antibody. J Biochem Mol Toxicol 2000, 14:95-101
36. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003, 2:717-726
37. Saklatvala J, Dean J, Clark A: Control of the expression of inflammatory response genes. Biochem Soc Symp 2003, 70:95-106
38. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL: Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47:185-201
39. Herlaar E, Brown Z: p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999, 5:439-447
40. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991, 1072:129-157
41. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N: Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001, 98:1429-1439
42. Shi L, Kishore R, McMullen MR, Nagy LE: Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1. Am J Physiol 2002, 282:C1205-C1211
43. Droin NM, Pinkoski MJ, Dejardin E, Green DR: Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol 2003, 23:7638-7647
44. Moake JL: Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002, 126:1430-1433
45. Hosack DA, Dennis Jr G, Sherman BT, Lane HC, Lempicki RA: Identifying biological themes within lists of genes with EASE. Genome Biol 2003, 4:R70
46. Thomson S, Mahadevan LC, Clayton AL: MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction. Semin Cell Dev Biol 1999, 10:205-214
47. Liang G, Wolfgang CD, Chen BP, Chen TH, Hai T: ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 1996, 271:1695-1701
48. Kool J, Hamdi M, Cornelissen-Steijger P, van der Eb AJ, Terleth C, van Dam H: Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAP kinases and ATF-2. Oncogene 2003, 22:4235-4242
49. Inoue K, Zama T, Kamimoto T, Aoki R, Ikeda Y, Kimura H, Hagiwara M: TNFalpha-induced ATF3 expression is bidirectionally regulated by the JNK and ERK pathways in vascular endothelial cells. Genes Cells 2004, 9:59-70
50. Bradley MN, Zhou L, Smale ST: C/EBPbeta regulation in lipopolysaccharide-stimulated macrophages. Mol Cell Biol 2003, 23:4841-4858
51. Hanlon M, Sturgill TW, Sealy L: ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor. J Biol Chem 2001, 276:38449-38456
52. Wang Q, Doerschuk CM: The signaling pathways induced by neutrophil-endothelial cell adhesion. Antioxid Redox Signal 2002, 4:39-47
53. Vestweber D, Blanks JE: Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999, 79:181-213
54. Therrien M, Wong AM, Rubin GM: CNK, a RAF-binding multidomain protein required for RAS signaling. Cell 1998, 95:343-353
55. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, Swing DA, Jenkins NA, Tsichlis PN, Copeland NG: Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 1997, 11:688-700
56. Turgeon B, Lang BF, Meloche S: The protein kinase ERK3 is encoded by a single functional gene: genomic analysis of the ERK3 gene family. Genomics 2002, 80:673-680
57. Remuzzi G, Ruggenenti P: The hemolytic uremic syndrome. Kidney Int 1995, 48:2-19
58. Coratelli P, Buongiorno E, Passavanti G: Endotoxemia in hemolytic uremic syndrome. Nephron 1988, 50:365-367
59. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C: The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997, 175:611-620
60. Barrett TJ, Potter ME, Wachsmuth IK: Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 1989, 57:3434-3437
61. Ikeda M, Ito S, Honda M: Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Pediatr Nephrol 2004, 5:485-489
62. Smith WE, Kane AV, Campbell ST, Acheson DW, Cochran BH, Thorpe CM: Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003, 71:1497-1504
63. Thorpe CM, Smith WE, Hurley BP, Acheson DW: Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001, 69:6140-6147
64. Thorpe CM, Hurley BP, Lincicome LL, Jacewicz MS, Keusch GT, Acheson DW: Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun 1999, 67:5985-5993
65. Foster GH, Tesh VL: Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha. J Leukoc Biol 2002, 71:107-114
66. Shimada O, Ishikawa H, Tosaka-Shimada H, Atsumi S: Exocytotic secretion of toxins from macrophages infected with Escherichia coli O157. Cell Struct Funct 1999, 24:247-253
67. Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM: Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol 1997, 11:556-559
68. van Setten PA, van Hinsbergh VW, van den Heuvel LP, Preyers F, Dijkman HB, Assmann KJ, van der Velden TJ, Monnens LA: Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr Res 1998, 43:759-767
69. Palermo MS, Alves Rosa MF, Van Rooijen N, Isturiz MA: Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol 1999, 116:462-467
70. Marshall CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994, 4:82-89
71. Fan H, Derynck R: Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J 1999, 18:6962-6972
72. Gechtman Z, Alonso JL, Raab G, Ingber DE, Klagsbrun M: The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J Biol Chem 1999, 274:28828-28835
73. Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A: Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J 2002, 363:211-221
74. Rizoli SB, Rotstein OD, Kapus A: Cell volume-dependent regulation of L-selectin shedding in neutrophils. A role for p38 mitogen-activated protein kinase. J Biol Chem 1999, 274:22072-22080
75. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398
76. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H: The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999, 18:4969-4980
77. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O'Brien AD, Samuel JE: Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 1993, 61:3392-3402
78. Taylor Jr FB, Tesh VL, DeBault L, Li A, Chang AC, Kosanke SD, Pysher TJ, Siegler RL: Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999, 154:1285-1299
79. Ashkenazi S: Role of bacterial cytotoxins in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Annu Rev Med 1993, 44:11-18
80. Ray PE, Liu XH: Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 2001, 16:823-839
81. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088
82. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999, 189:615-625
83. Kaisho T, Akira S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589:1-13
84. Harrison LM, van Haaften WC, Tesh VL: Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 2004, 72:2618-2627
85. Vitetta ES: Immunotoxins and vascular leak syndrome. Cancer J 2000, 6(Suppl 3):S218-S224
86. Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA: Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 2002, 62:832-845
87. Palermo M, Alves-Rosa F, Rubel C, Fernandez GC, Fernandez-Alonso G, Alberto F, Rivas M, Isturiz M: Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol 2000, 119:77-83
88. Tesh VL, Samuel JE, Perera LP, Sharefkin JB, O'Brien AD: Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis 1991, 164:344-352
89. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS: Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999, 19:91-104
90. DaSilva L, Cote D, Roy C, Martinez M, Duniho S, Pitt ML, Downey T, Dertzbaugh M: Pulmonary gene expression profiling of inhaled ricin. Toxicon 2003, 41:813-822
91. Proulx F, Turgeon JP, Litalien C, Mariscalco MM, Robitaille P, Seidman E: Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Pediatr Infect Dis J 1998, 17:899-904
92. van de Kar NC, Sauerwein RW, Demacker PN, Grau GE, van Hinsbergh VW, Monnens LA: Plasma cytokine levels in hemolytic uremic syndrome. Nephron 1995, 71:309-313
93. Murata A, Shimazu T, Yamamoto T, Taenaka N, Nagayama K, Honda T, Sugimoto H, Monden M, Matsuura N, Okada S: Profiles of circulating inflammatory- and anti-inflammatory cytokines in patients with hemolytic uremic syndrome due to E. coli O157 infection. Cytokine 1998, 10:544-548
94. Andreoli SP: The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 1999, 8:459-464
95. Proulx F, Toledano B, Phan V, Clermont MJ, Mariscalco MM, Seidman EG: Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2002, 52:928-934
96. Sukhatme VP, Kartha S, Toback FG, Taub R, Hoover RG, Tsai-Morris CH: A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res 1987, 1:343-355
97. Hallahan DE, Sukhatme VP, Sherman ML, Virudachalam S, Kufe D, Weichselbaum RR: Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 1991, 88:2156-2160
98. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, Stern DM: Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999, 274:15030-15040
99. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM: Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997, 272:20131-20138
100. Carl M, Akagi Y, Weidner S, Isaka Y, Imai E, Rupprecht HD: Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis. Kidney Int 2003, 63:1302-1312
101. Silverman ES, Collins T: Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999, 154:665-670
102. Khachigian LM, Collins T: Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ Res 1997, 81:457-461
103. Maltzman JS, Carman JA, Monroe JG: Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol Cell Biol 1996, 16:2283-2294
104. Maltzman JS, Carmen JA, Monroe JG: Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1. J Exp Med 1996, 183:1747-1759
105. Srivastava S, Weitzmann MN, Kimble RB, Rizzo M, Zahner M, Milbrandt J, Ross FP, Pacifici R: Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 1998, 102:1850-1859
106. Robson WL, Leung AK, Kaplan BS: Hemolytic-uremic syndrome. Curr Probl Pediatr 1993, 23:16-33
107. Richardson SE, Karmali MA, Becker LE, Smith CR: The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988, 19:1102-1108
108. Drummond KN: Hemolytic uremic syndrome - then and now. N Engl J Med 1985, 312:116-118
109. Proesmans W, Geet CV: Fibrinolysis in the hemolytic uremic syndrome. Pediatr Nephrol 2002, 17:871-874
110. Van Geet C, Proesmans W, Arnout J, Vermylen J, Declerck PJ: Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 1998, 54:1324-1330
111. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI: Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002, 346:23-32